CTXR

Citius Pharmaceuticals, Inc. [CTXR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CTXR Stock Summary

Top 10 Correlated Stocks

CTXR


In the News

04:30 29 Nov 2023 CTXR

Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023

CRANFORD, N.J. , Sept. 18, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, has rescheduled its participation in Sidoti's Small-Cap Virtual Conference to November 2023 due to funeral services for the late Howard Safir, a long-time member of the Citius Board.

04:30 29 Nov 2023 CTXR

Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023

CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two investor conferences in September 2023.

06:55 29 Nov 2023 CTXR

Citius Pharmaceuticals: Steer Clear From This One

The article provides an updated analysis of Citius Pharmaceuticals following a previous piece in February 2023. Citius' lead therapy has a midsummer 2023 PDUFA; it has generated excitement among investors, although it is unlikely to generate alpha. Its second lead therapy is likely to disappoint.

08:30 29 Nov 2023 CTXR

Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023

CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023.

10:51 29 Nov 2023 CTXR

After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)

The heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

07:36 29 Nov 2023 CTXR

Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days

Citius Pharmaceuticals, Inc. has a handful of catalysts set to occur in the next few months. Of these, some are critical to extending its cash runway far enough to reach commercialization of its major products, and are therefore a "must complete" by the company.

04:30 29 Nov 2023 CTXR

Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

UPDATED: Chairman & CEO of Citius, Leonard Mazur, to present September 12, 2022 at 8:30am ET CRANFORD, N.J. , Sept. 8, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C.

06:40 29 Nov 2023 CTXR

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as earlier indicated.

09:30 29 Nov 2023 CTXR

Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022

CRANFORD, N.J. , May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C.

09:00 29 Nov 2023 CTXR

3 Reddit Stocks to Buy in May

These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond The post 3 Reddit Stocks to Buy in May appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in savings or $5 million.

CTXR Financial details

Company Rating
Buy
Market Cap
125.48M
Income
-30.59M
Revenue
0
Book val./share
0.64
Cash/share
0.22
Dividend
-
Dividend %
-
Employees
21
Optionable
No
Shortable
Yes
Earnings
20 Dec 2023
P/E
-3.85
Forward P/E
1.82
PEG
-0
P/S
-
P/B
1.2
P/C
3.48
P/FCF
-4.25
Quick Ratio
5.75
Current Ratio
7.1
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
-73.31K
EPS next Y
0.42
EPS next Q
-0.04
EPS this Y
9.52%
EPS next Y
-100%
EPS next 5Y
-100%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-23.47%
-
-
-
-
SMA20
4.05%
SMA50
-1.28%
SMA100
-36.89%
Inst Own
9.98%
Inst Trans
0.58%
ROA
-28%
ROE
-31%
ROC
-0.33%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
158.86M
Shs Float
146.53M
-
-
-
-
Target Price
-
52W Range
0.6-1.71
52W High
-
52W Low
-
RSI
50.57
Rel Volume
0.71
Avg Volume
650.97K
Volume
463.75K
Perf Week
0.17%
Perf Month
4.84%
Perf Quarter
-40.21%
Perf Half Y
-30.43%
-
-
-
-
Beta
1.412
-
-
Volatility
0.01%, 0.03%
Prev Close
-2.07%
Price
0.7653
Change
-2.06%

CTXR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-09-30

Metric History 2018-09-302019-09-302020-09-302021-09-30 2022-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.17-0.77-0.45-0.21-0.23
Operating cash flow per share
-1.05-0.62-0.43-0.22-0.19
Free cash flow per share
-1.05-0.62-0.43-0.59-0.19
Cash per share
0.860.390.350.650.29
Book value per share
2.61.210.861.220.7
Tangible book value per share
0.640.170.130.590.24
Share holders equity per share
2.61.210.861.220.7
Interest debt per share
0.020.010.030.010.01
Market cap
17.92M15.27M40.73M220.46M176.76M
Enterprise value
8.91M7.55M28.22M151.24M135.73M
P/E ratio
-1.43-0.98-2.3-9.53-5.25
Price to sales ratio
00000
POCF ratio
-1.58-1.23-2.41-9.09-6.23
PFCF ratio
-1.58-1.23-2.41-3.43-6.23
P/B Ratio
0.640.631.211.671.72
PTB ratio
0.640.631.211.671.72
EV to sales
00000
Enterprise value over EBITDA
-0.71-0.49-1.62-6.56-4.13
EV to operating cash flow
-0.79-0.61-1.67-6.24-4.79
EV to free cash flow
-0.79-0.61-1.67-2.35-4.79
Earnings yield
-0.7-1.02-0.43-0.1-0.19
Free cash flow yield
-0.63-0.81-0.42-0.29-0.16
Debt to equity
0.010.010.040.010.01
Debt to assets
0.010.010.030.010.01
Net debt to EBITDA
0.720.50.7231.25
Current ratio
3.161.723.4118.289.84
Interest coverage
-870.64-948.63-1.13K-2.17K-132.52
Income quality
0.90.80.961.050.84
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.680.720.660.480.6
Capex to operating cash flow
0001.650
Capex to revenue
00000
Capex to depreciation
00-0.01-242.660
Stock based compensation to revenue
00000
Graham number
8.264.582.952.411.91
ROIC
-0.54-0.64-0.49-0.18-0.33
Return on tangible assets
-1.25-1.95-1.18-0.31-0.74
Graham Net
0.620.160.10.560.21
Working capital
6.88M3.33M9.88M68.83M40.03M
Tangible asset value
6.88M3.39M4.92M64.04M34.68M
Net current asset value
6.88M3.33M3.88M63.17M33.99M
Invested capital
0.010.010.040.010.01
Average receivables
409.17K409.17K000
Average payables
1.09M2.14M2.28M1.57M1.22M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.45-0.64-0.52-0.17-0.33
Capex per share
000-0.370

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q3

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.06-73.31K-0.02-0.07-0.06
Operating cash flow per share
-0.05-58.1K-0.03-0.05-0.06
Free cash flow per share
-0.05-58.1K-0.03-0.05-0.06
Cash per share
0.33382.68K0.250.20.22
Book value per share
0.75943.36K0.690.620.64
Tangible book value per share
0.28318.16K0.220.160.19
Share holders equity per share
0.75943.36K0.690.620.64
Interest debt per share
0.017.46K-0.0200
Market cap
134.44M131.89115.51M171.11M184.53M
Enterprise value
87.12M-41.03M79.25M142.63M151.78M
P/E ratio
-3.810-8.04-4.06-5.44
Price to sales ratio
00000
POCF ratio
-17.430-23.94-21.79-19.26
PFCF ratio
-17.430-23.94-21.79-19.26
P/B Ratio
1.2301.151.881.89
PTB ratio
1.2301.151.881.89
EV to sales
00000
Enterprise value over EBITDA
-9.885.57-11-13.41-17.6
EV to operating cash flow
-11.36.48-16.43-18.16-15.84
EV to free cash flow
-11.36.48-16.43-18.16-15.84
Earnings yield
-0.07-60.59K-0.03-0.06-0.05
Free cash flow yield
-0.06-48.01K-0.04-0.05-0.05
Debt to equity
0.010.010.010.010.01
Debt to assets
0.010.010.010.010
Net debt to EBITDA
5.375.575.032.683.8
Current ratio
11.49.849.335.627.1
Interest coverage
-168.18-55.991.9135.230
Income quality
0.870.791.340.751.13
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.570.60.620.660.62
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
1.011.25M0.6210.89
ROIC
-0.08-0.08-0.07-0.12-0.09
Return on tangible assets
-0.17-0.18-0.08-0.3-0.2
Graham Net
0.26285.68K0.180.110.14
Working capital
46.37M40.03M37.78M28.69M35.32M
Tangible asset value
41.59M34.68M32.29M23.06M29.55M
Net current asset value
40.85M33.99M31.65M22.47M29.01M
Invested capital
0.010.010.010.010.01
Average receivables
00000
Average payables
1.7M1.43M1.35M2.13M2.9M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.08-0.08-0.04-0.12-0.09
Capex per share
00000

CTXR Frequently Asked Questions

What is Citius Pharmaceuticals, Inc. stock symbol ?

Citius Pharmaceuticals, Inc. is a US stock , located in Cranford of Nj and trading under the symbol CTXR

What is Citius Pharmaceuticals, Inc. stock quote today ?

Citius Pharmaceuticals, Inc. stock price is $0.7653 today.

Is Citius Pharmaceuticals, Inc. stock public?

Yes, Citius Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap